Publications by authors named "Mariana Sacchi"
Background And Objectives: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL.
Methods: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL.
Cerebellar transcranial direct current stimulation (ctDCS) has emerged as a promising, non-invasive, and safe neuromodulatory intervention capable of reducing ataxia symptoms and restoring cerebellum-motor connectivity. However, previous studies have only applied ctDCS in isolation, without association with specific training. This study aimed to assess the effect of ctDCS combined with gait training on functional mobility, balance, and symptoms and severity of ataxia.
View Article and Find Full Text PDFArticle Synopsis
- Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising long-term results as a monotherapy for relapsed or refractory large B-cell lymphoma (LBCL) in the EPCORE NHL-1 study, with a 63.1% overall response rate and a 40.1% complete response rate after a median follow-up of 25.1 months.
- The estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively, with 64.2% of complete responders maintaining their response at that time.
- Most treatment-emergent adverse events were manageable, with cytokine release syndrome
Article Synopsis
- - The study evaluated the effectiveness of epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) by comparing it to other therapies used after at least two prior treatments, using advanced statistical methods to ensure fair comparisons.
- - Epcoritamab showed significantly better response and overall survival rates than traditional chemoimmunotherapy (CIT) and other novel therapies, such as polatuzumab-based and tafasitamab-based regimens.
- - However, there were no significant differences in response or survival rates when comparing epcoritamab to CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma.
Introduction: Despite new therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatments with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents continue to be commonly used.
Methods: This retrospective study utilized longitudinal data from 4226 real-world electronic health records to characterize outcomes in patients with R/R DLBCL. Eligible patients were diagnosed with DLBCL between January 2010 and March 2022 and had R/R disease treated with ≥ 1 prior systemic line of therapy (LOT), including ≥ 1 anti-CD20-containing regimen.
Article Synopsis
- A study evaluated patient-reported outcomes in adults with relapsed or refractory large B-cell lymphoma treated with epcoritamab, a new monotherapy.
- Patients completed assessments to measure quality of life and symptoms, and the results showed significant improvements in their scores over the treatment period.
- The majority of patients expressed satisfaction with the treatment, highlighting its potential effectiveness in enhancing their quality of life.
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with R/R cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms.
View Article and Find Full Text PDFArticle Synopsis
- Epcoritamab is a bispecific antibody that helps T cells attack and kill malignant B cells, showing strong results in treating B-cell non-Hodgkin lymphoma during previous trials.
- In a phase I/II study, patients with relapsed or refractory large B-cell lymphoma received weekly doses of epcoritamab for up to several months to assess its effectiveness.
- Results showed a 63.1% overall response rate and 38.9% complete response rate among 157 patients with manageable side effects, suggesting it is a promising treatment for difficult cases of lymphoma.
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles.
View Article and Find Full Text PDFPurpose: Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed cHL.
Methods: Patients 18 years of age or older with untreated, advanced-stage (defined as III to IV and IIB with unfavorable risk factors) cHL were eligible for Cohort D of this multicenter, noncomparative, phase II trial.
Purpose Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias.
View Article and Find Full Text PDF